Genomed

Genomed ROA

The Return on Assets (ROA) of Genomed (GEN.WA) as of Nov 2, 2026 is 20.57 %. In the previous year, Return on Assets (ROA) was 8.91 % — a change of 130.75% (higher).

ROA

20.57 %

YoY

130.75%

Last updated:

In 2025, Genomed's return on assets (ROA) was 20.57 %, a 130.75% increase from the 8.91 % ROA in the previous year.

The Genomed ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
15.90 PLN
Jan 1, 2019
11.18 PLN
Jan 1, 2020
4.12 PLN
Jan 1, 2021
11.99 PLN
Jan 1, 2022
3.26 PLN
Jan 1, 2023
7.64 PLN
Jan 1, 2024
8.91 PLN
Jan 1, 2025
20.57 PLN
The Genomed ROA history
YEARROAYoY
20.57 %+130.75%
8.91 %+16.66%
7.64 %+134.63%
3.26 %-72.83%
11.99 %+190.99%
4.12 %-63.16%
11.18 %-29.68%
15.90 %-24.44%
21.04 %+441.34%
3.89 %+5,748.41%
0.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

ROA Details

Understanding Genomed's Return on Assets (ROA)

Genomed's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Genomed's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Genomed's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Genomed’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Genomed stock

Return on Assets (ROA) of Genomed is 20.57 % in 2025.

Return on Assets (ROA) of Genomed changed from 8.91 % to 20.57 %, representing a 130.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Genomed since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Genomed with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Genomed

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Genomed